{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:23:59Z","timestamp":1787228639597,"version":"build-2736575974"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.tranon.2026.102920","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T21:43:14Z","timestamp":1784238194000},"page":"102920","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3084-2500","authenticated-orcid":false,"given":"Eduardo","family":"Chuluyan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8932-716X","authenticated-orcid":false,"given":"Daniel","family":"Grasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3138-7335","authenticated-orcid":false,"given":"Analia","family":"Pasqua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1371-3909","authenticated-orcid":false,"given":"Carla","family":"Remolins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7190-6182","authenticated-orcid":false,"given":"Andrea Paes","family":"de Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-4923-7537","authenticated-orcid":false,"given":"Kevin","family":"Matamoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Guerrieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Kohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florencia","family":"Gottardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9080-2108","authenticated-orcid":false,"given":"Martin","family":"Ledesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0389-5546","authenticated-orcid":false,"given":"Juan","family":"Garona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Davio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0503-5897","authenticated-orcid":false,"given":"Agustin","family":"Yaneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2167-1298","authenticated-orcid":false,"given":"Maria Noe","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Papademetrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8748-5415","authenticated-orcid":false,"given":"Maria Eugenia","family":"Pasqualini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Sarotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Garnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4688-8765","authenticated-orcid":false,"given":"Brice","family":"Chanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Fraunhoffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6161-8483","authenticated-orcid":false,"given":"Nelson","family":"Dusetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1822-2237","authenticated-orcid":false,"given":"Juan","family":"Iovanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102920_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.tranon.2026.102920_bib0002","first-page":"36","article-title":"Genetics and biology of pancreatic ductal adenocarcinoma","volume":"39","author":"Ying","year":"2025","journal-title":"Genes Dev."},{"key":"10.1016\/j.tranon.2026.102920_bib0003","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.102920_bib0004","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1038\/ng.3398","article-title":"Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma","volume":"47","author":"Moffitt","year":"2015","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tranon.2026.102920_bib0005","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nature16965","article-title":"Genomic analyses identify molecular subtypes of pancreatic cancer","volume":"531","author":"Bailey","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.tranon.2026.102920_bib0006","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1158\/1078-0432.CCR-19-1467","article-title":"Purity independent subtyping of tumors (PurIST), A clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer","volume":"26","author":"Rashid","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102920_bib0007","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2026.102920_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2026.115164","article-title":"Stage-dependent transcriptional analysis reveals key genes driving pancreatic ductal adenocarcinoma progression and therapeutic vulnerabilities","author":"Chuluyan","year":"2026","journal-title":"IScience"},{"key":"10.1016\/j.tranon.2026.102920_bib0009","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41575-018-0005-x","article-title":"Therapeutic developments in pancreatic cancer: current and future perspectives","volume":"15","author":"Neoptolemos","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tranon.2026.102920_bib0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102920_bib0011","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41588-019-0566-9","article-title":"Transcription phenotypes of pancreatic cancer are driven by genomic events during tumor evolution","volume":"52","author":"Chan-Seng-Yue","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tranon.2026.102920_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102858","article-title":"Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic cancer","volume":"57","author":"Nicolle","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.tranon.2026.102920_bib0013","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1016\/j.celrep.2017.11.003","article-title":"Pancreatic adenocarcinoma therapeutic targets revealed by tumor-stroma cross-talk analyses in patient-derived xenografts","volume":"21","author":"Nicolle","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.tranon.2026.102920_bib0014","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/bjc.2014.215","article-title":"Oncogenic KRAS signalling in pancreatic cancer","volume":"111","author":"Eser","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tranon.2026.102920_bib0015","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase Alfa with Nab-Paclitaxel plus Gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102920_bib0016","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance Olaparib for Germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102920_bib0017","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.tranon.2026.102920_bib0018","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2208470","article-title":"Sotorasib in KRAS p.G12C\u2013Mutated advanced pancreatic cancer","volume":"388","author":"Strickler","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102920_bib0019","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102920_bib0020","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","article-title":"FOLFIRINOX or Gemcitabine as adjuvant therapy for pancreatic cancer","volume":"379","author":"Conroy","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102920_bib0021","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1158\/1078-0432.CCR-14-1591","article-title":"Combined MEK and PI3K inhibition in a mouse model of pancreatic cancer","volume":"21","author":"Alagesan","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102920_bib0022","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/nm.1890","article-title":"Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers","volume":"14","author":"Engelman","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.102920_bib0023","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1158\/1078-0432.CCR-13-3377","article-title":"Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-akt oncogenic dependence in pancreatic ductal adenocarcinoma","volume":"20","author":"Wong","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102920_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105936","article-title":"Clinical management of common toxicities with inhibitors targeting the PI3K\/AKT\/mTOR pathway in breast cancer","volume":"11","author":"Jhaveri","year":"2026","journal-title":"ESMO Open."},{"key":"10.1016\/j.tranon.2026.102920_bib0025","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1158\/1078-0432.CCR-24-3296","article-title":"Mitochondria targeting of oxidative phosphorylation inhibitors to alleviate hypoxia and enhance anticancer treatment efficacy","volume":"31","author":"Beerkens","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2026.102920_bib0026","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1200\/JCO.2008.20.0238","article-title":"Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer","volume":"27","author":"Van Cutsem","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102920_bib0027","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf284","article-title":"Phase I study of palbociclib with cisplatin or carboplatin in the management of patients with advanced pancreatic cancer","volume":"30","author":"Alese","year":"2025","journal-title":"Oncologist"},{"key":"10.1016\/j.tranon.2026.102920_bib0028","doi-asserted-by":"crossref","first-page":"482","DOI":"10.15252\/emmm.201606975","article-title":"Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts","volume":"9","author":"Bian","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.tranon.2026.102920_bib0029","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/s41591-018-0052-4","article-title":"An inhibitor of oxidative phosphorylation exploits cancer vulnerability","volume":"24","author":"Molina","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.102920_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110642","article-title":"Etomoxir repurposed as a promiscuous fatty acid mimetic chemoproteomic probe","volume":"27","author":"Choi","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.tranon.2026.102920_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003731","article-title":"Anti-CCR4 treatment depletes regulatory T cells and leads to clinical activity in a canine model of advanced prostate cancer","volume":"10","author":"Maeda","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tranon.2026.102920_bib0032","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102920_bib0033","doi-asserted-by":"crossref","first-page":"254","DOI":"10.2174\/156800911794519716","article-title":"Marizomib, a proteasome inhibitor for all seasons: preclinical profile and a framework for clinical trials","volume":"11","author":"Potts","year":"2011","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.tranon.2026.102920_bib0034","doi-asserted-by":"crossref","first-page":"17945","DOI":"10.1073\/pnas.1316796110","article-title":"Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans","volume":"110","author":"Sugiyama","year":"2013","journal-title":"Proc. Natl. Acad. Sci."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326002561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T11:26:46Z","timestamp":1787225206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326002561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":34,"alternative-id":["S1936523326002561"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102920","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pathway-driven therapeutic stratification in pancreatic ductal adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102920","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 inserm. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102920"}}